Clinical Trials Browser

OTHER × Interventional × Sunitinib × Clear all

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Phase 2 Recruiting

Neoplasm Metastasis, Osteosarcoma

NCT02068586 2026-03-16

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Phase 2 Active not recruiting

Uveal Melanoma

NCT06955169 2026-02-17

MOMENTUM-1

Phase 2 Recruiting

Meningioma

NCT02693535 2026-02-13

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03900793 2026-02-03

Losartan + Sunitinib in Treatment of Osteosarcoma

Phase 1 Recruiting

Osteosarcoma

NCT06726421 2026-01-15

STROKER

Phase 3 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03541902 2026-01-09

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Urologic Neoplasms

NCT00329043 2025-12-26

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT00715442 2025-12-23

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT04394975 2025-11-28

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Phase 3 Completed

Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1

NCT06208748 2025-10-31

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

Phase 2 Active not recruiting

GastrointestinalSarcoma

Sarcoma, Gastrointestinal Stromal Tumors

NCT07165418 2025-09-10

A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI

Phase 3 Not yet recruiting

Carcinoma, Renal Cell

NCT05366816 2025-09-09

ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST

Phase 2 Recruiting

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00930033 2025-09-05

CARMENA

Phase 3 Completed

Carcinoma, Renal Cell

NCT03463460 2025-08-24

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Phase 2 Recruiting

Thymoma

NCT01286896 2025-07-10

Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Malignant Solid Tumour

NCT00437372 2025-05-02

Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

Phase 1 Completed

GynecologicHead & NeckThoracic

Head and Neck Neoplasms, Neoplasms, Nervous System Neoplasms, Pelvic Neoplasms, Thoracic Neoplasms

NCT06940349 2025-04-23

COPS-01

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors Refractory to Standard Therapy

NCT02230176 2025-04-20

OCCLURANDOM

Phase 2 Completed

Somatostatinoma

NCT06222593 2025-02-17

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT00961571 2025-02-12

Sunitinib and Capecitabine for First Line Colon Cancer

Phase 2 Terminated

50 enrolled 7 charts

Gastrointestinal

Colorectal Neoplasms

NCT03109015 2024-10-08

ASSET

Phase 2 Completed

7 enrolled 18 charts

Carcinoma, Renal Cell

NCT03277924 2024-08-13

ImmunoSarc

Phase 1/2 Completed

Chondrosarcoma, Extraskeletal Myxoid, Bone Neoplasms, Chondrosarcoma, Hemangioendothelioma, Hemangiosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

NCT03905889 2024-06-25

A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

Phase 1 Terminated

Carcinoma, Renal Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05949424 2023-11-29

OPTI-DOSE

Phase 4 Unknown

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT01517243 2023-09-21

Phase II Study of Alternating Sunitinib and Temsirolimus

Phase 2 Completed

37 enrolled 13 charts

Carcinoma, Renal Cell

NCT00656669 2023-05-23

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

Phase NA Completed

23 enrolled 12 charts

Breast Neoplasms

NCT05816642 2023-04-18

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Phase NA Unknown

Carcinoma, Renal Cell

NCT00270413 2022-11-22

SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00520533 2022-10-12

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Phase 1 Terminated

8 enrolled 18 charts

Carcinoma, Renal Cell, Mycobacterium Infections, Nontuberculous

NCT00936832 2022-08-30

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Phase 2 Withdrawn

Gastrointestinal

Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT01371201 2022-08-04

FIRSTMAPPP

Phase 2 Completed

Paraganglioma

NCT02450123 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Phase NA Completed

Other solid neoplasm

Refractory Solid Tumors

NCT03170180 2022-06-15

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT01164202 2022-03-18

SATURNE

Phase 2/3 Completed

78 enrolled 9 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03035630 2022-02-15

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Phase 2 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02689167 2021-11-29

SURF

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT00695292 2021-11-22

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Phase 2 Completed

37 enrolled 10 charts

Small Cell Lung Carcinoma

NCT01620216 2021-11-04

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Phase 2 Terminated

12 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02959554 2021-09-08

NIVOSWITCH

Phase 2 Terminated

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT02164240 2021-06-14

SURE

Phase 1 Completed

14 enrolled 8 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01185366 2021-04-28

Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Phase 2 Terminated

73 enrolled 17 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00853125 2021-04-27

Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Phase 2 Terminated

10 enrolled 8 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02960906 2021-04-26

BIONIKK

Phase 2 Completed

Clear-cell metastatic renal cell carcinoma

NCT03025893 2021-04-19

STELLAR

Phase 2/3 Unknown

Brain Neoplasms, Glioblastoma

NCT01636908 2021-04-15

ICK

Phase NA Completed

Neoplasms

NCT00541008 2021-02-21

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

Phase 2 Completed

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02555748 2021-01-12

SUP-R

Phase 4 Completed

Carcinoma, Renal Cell

NCT01190241 2020-11-20

TSAP

Phase NA Terminated

Neoplasm Metastasis